GlassScriptPhysician profile
Rajesh Boorgu
NPI 1033117817
$3,980.73
in general payments reported to CMS, 2019-2025
29 companies · $866 in 2025
The $866 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $304 · 2021: $659 · 2022: $484 · 2023: $549 · 2024: $792 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Education: $33.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.33 |
| Education | $33.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $532.09 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $488.53 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $381.34 | 2019-2025 | Tavneos, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $338.43 | 2020-2025 | |
| Opko Pharmaceuticals, LLC | $253.63 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $231.73 | 2019-2025 | Jynarque, Voyxact |
| Novo Nordisk INC | $215.74 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $167.03 | 2019-2024 | Lokelma |
| Mallinckrodt Hospital Products INC. | $160.85 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.85 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $110.18 | 2023-2024 | Tarpeyo |
| Lilly USA, LLC | $102.85 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $97.10 | 2022-2023 | Jesduvroq |
| Ardelyx, INC. | $88.05 | 2024-2025 | Ibsrela |
| Abbott Laboratories | $83.82 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $82.28 | 2022-2024 | Nxstage System One, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.94 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $64.64 | 2019-2023 | Soliris |
| Mallinckrodt Enterprises LLC | $61.43 | 2019 | |
| Bard Peripheral Vascular, INC. | $56.30 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $55.73 | 2022-2023 | Lupkynis |
| Baxter Healthcare | $46.59 | 2021-2023 | Gambro - Accute |
| Vantive US Healthcare LLC | $25.39 | 2025 | Renal - Pd |
| Genzyme Corporation | $22.62 | 2023 | |
| Dexcom, INC. | $16.12 | 2021 | |
| Nxstage Medical, INC. | $16.05 | 2021 | |
| Kyowa Kirin, INC. | $14.98 | 2024 | Crysvita |
| Horizon Therapeutics Plc | $14.33 | 2021 | |
| Medtronic, INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Boorgu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.